Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

References for PMC Articles for PubMed (Select 23047475)

1.

Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.

Xiao Y, Zou P, Wang J, Song H, Zou J, Liu L.

J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):328-33. doi: 10.1007/s11596-012-0057-z. Epub 2012 Jun 9.

PMID:
22684553
2.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T.

Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12.

3.

BCR-ABL1 kinase: hunting an elusive target with new weapons.

Skorski T.

Chem Biol. 2011 Nov 23;18(11):1352-3. doi: 10.1016/j.chembiol.2011.11.001.

4.

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.

Gruber FX, Ernst T, Porkka K, Engh RA, Mikkola I, Maier J, Lange T, Hochhaus A.

Leukemia. 2012 Jan;26(1):172-7. doi: 10.1038/leu.2011.187. Epub 2011 Aug 5. No abstract available.

PMID:
21818112
5.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.

Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.

6.

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.

White DL, Hughes TP.

Curr Hematol Malig Rep. 2011 Jun;6(2):88-95. doi: 10.1007/s11899-011-0087-9. Review.

PMID:
21448598
8.

BCR/ABL stimulates WRN to promote survival and genomic instability.

Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T.

Cancer Res. 2011 Feb 1;71(3):842-51. doi: 10.1158/0008-5472.CAN-10-1066. Epub 2010 Dec 1.

9.

Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.

Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JA, Wang M, Karran L, Dyer MJ, Forrest D, Page K, Eaves CJ, Woolfson A.

Leukemia. 2010 Oct;24(10):1817-21. doi: 10.1038/leu.2010.179. Epub 2010 Aug 26. No abstract available.

PMID:
20739956
10.

Incorporation of dUTP does not mediate mutation of A:T base pairs in Ig genes in vivo.

Sharbeen G, Cook AJ, Lau KK, Raftery J, Yee CW, Jolly CJ.

Nucleic Acids Res. 2010 Dec;38(22):8120-30. doi: 10.1093/nar/gkq682. Epub 2010 Aug 12.

11.

Chronic myeloid leukemia: mechanisms of blastic transformation.

Perrotti D, Jamieson C, Goldman J, Skorski T.

J Clin Invest. 2010 Jul;120(7):2254-64. doi: 10.1172/JCI41246. Epub 2010 Jul 1. Review.

12.

Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.

Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swale B, Milojkovic D, Reid A, Goldman J, Marin D.

Am J Hematol. 2009 Aug;84(8):517-22. doi: 10.1002/ajh.21457. Review.

PMID:
19544476
13.

Uracil in DNA and its processing by different DNA glycosylases.

Visnes T, Doseth B, Pettersen HS, Hagen L, Sousa MM, Akbari M, Otterlei M, Kavli B, Slupphaug G, Krokan HE.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):563-8. doi: 10.1098/rstb.2008.0186. Review.

14.

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T.

Cancer Res. 2008 Apr 15;68(8):2576-80. doi: 10.1158/0008-5472.CAN-07-6858.

15.

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T.

Leukemia. 2008 Oct;22(10):1969-72. doi: 10.1038/leu.2008.78. Epub 2008 Apr 10. No abstract available.

16.

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Melo JV, Barnes DJ.

Nat Rev Cancer. 2007 Jun;7(6):441-53. Review.

PMID:
17522713
17.

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

Jiang X, Saw KM, Eaves A, Eaves C.

J Natl Cancer Inst. 2007 May 2;99(9):680-93.

18.

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW.

Mol Cell Biol. 2006 Aug;26(16):6082-93.

19.

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T.

Blood. 2006 Jul 1;108(1):319-27. Epub 2006 Mar 9.

20.

Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.

Marley SB, Gordon MY.

Clin Sci (Lond). 2005 Jul;109(1):13-25. Review.

PMID:
15966868
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk